Skip to main content

Table 2 Mean changes [and 95% CI] from baseline to 6 months follow-up in clinical, biohumoral, echocardiographic, and exercise test parameters

From: Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial

 

Empagliflozin (n = 22)

Sitagliptin (n = 22)

p value

Clinical parameters

 Weight (kg)

− 1.6 [− 2.7/− 0.5]*

0.1 [− 1.1/1.2]

0.0315

 HR at rest (beat/min)

0.6 [− 1.6/2.8]

− 0.4 [− 4.5/3.7]

ns

 MAP rest (mmHg)

− 5.4 [− 10.7/0.0]

− 0.22 [− 7.6/7.2]

ns

Biohumoral parameters

 HbA1c (mmol/mol)

− 4.6 [− 7.4/− 1.8]*

− 4.9 [− 8.8/− 0.9]*

ns

 Total Cholesterol (mg/dL)

− 8 [− 21/5]

− 15 [− 30/0]

ns

 HDL-Cholesterol (mg/dL)

1.3 [− 1.4/4.0]

− 1.7 [− 4.2/0.9]

ns

 LDL-Cholesterol (mg/dL)

− 7 [− 19/6]

− 7 [− 18/3]

ns

 Triglycerides (mg/dL)

− 2 [− 28/24]

− 14 [− 33/6]

ns

 Haemoglobin (g/dL)

0.7 [0.2/1.1]*

− 0.5 [− 1/− 0.1]

0.0003

 Haematocrit (%)

2.0 [0.7/3.2]*

− 1.3 [− 2.6/0.0]

0.0006

 Creatinine (mg/dL)

− 0.1 [− 0.2/0.1]

− 0.0 [− 0.1/0.0]

ns

 eGFR (mL/min/1.73mq)

2.5 [− 3.7/8.7]

1.4 [− 1.8/4.6]

ns

 Uric acid (mg/dL)

− 1.5 [− 2.3/− 0.6]*

0.2 [− 0.3/0.6]

0.0023

 UAlb-UCreat-Ratio (mg/g)

6.1 [− 1.9/14.2]

5.0 [− 20.6/30.5]

ns

Echocardiography

 EDVi rest (mL/m2)

2.2 [− 0.9/5.2]

3.6 [− 1.0/6.3]

ns

 LVMi rest (g/m2)

4.5 [− 1.1/10.2]

1.1 [− 2.7/5.0]

ns

 LAVi rest (mL/m2)

0.5 [− 1.3/2.2]

2.0 [− 0.4/4.3]

ns

 CO rest, L/min

0.0 [− 0.6/0.6]

0.8 [− 0.3/1.4]

ns

 CO peak, L/min

0.7 [− 0.6/1.9]

0.9 [− 0.3/2.1]

ns

 LVEF rest (%)

0.1 [− 1.3/1.6]

2.1 [− 0.4/3.7]

ns

 LVEF peak (%)

− 0.7 [− 2.8/1.5]

2.0 [− 0.1/3.9]

ns

 S’ mean rest (cm/sec)

0.0 [− 0.8/0.9]

− 0.1 [− 1.0/0.8]

ns

 S’ mean peak (cm/sec)

0.4 [− 0.9/1.7]

− 0.2 [− 1.0/0.6]

ns

 ΔS’ mean

0.4 [− 0.8/1.5]

− 0.1 [− 1.0/0.8]

ns

 E/e’ rest (cm/sec)

− 0.5 [− 1.3/0.4]

− 1.0 [− 2.2/0.2]

ns

 E/e’ peak (cm/sec)

− 0.3 [− 1.5/0.9]

− 0.6 [− 1.5/0.5]

ns

Cardiopulmonary exercise test

 Workload (W)

5 [− 1/11]

2 [− 5/9]

ns

 HR at peak (beat/min)

3.0 [− 2.1/8.0]

1.3 [− 4.4/7.0]

ns

 HR at peak (%max)

1.9 [− 1.3/5.1]

0.8 [− 2.8/4.5]

ns

 RER peak

0.00 [− 0.03/0.04]

0.01 [− 0.02/0.03]

ns

 VO2/work slope

0.3 [− 0.5/1.1]

0.6 [− 0.2/1.4]

ns

 VO2 rest (mL/min/kg)

0.5 [− 0.1/1.2]

0.6 [− 0.1/1.4]

ns

 VE/VCO2 slope

0.3 [− 1.2/1.8]

1.3 [− 0.1/2.6]

ns

 O2 pulse peak (mL/bpm)

0.1 [− 0.7/1.0]

0.5 [− 0.2/1.2]

ns

 O2 pulse peak (%VO2peak)

2.8 [− 3.0/8.5]

3.0 [− 1.1/7.1]

ns

 AV O2 diff rest (mL/dL)

0.6 [− 0.7/1.8]

0.2 [− 1.0/1.4]

ns

 AV O2 diff peak (mL/dL)

− 0.1 [− 0.9/0.7]

− 0.2 [− 1.3/1.0]

ns

  1. *Indicates a statistically significant difference within groups, p value indicates the level of statistical significance of the interaction term time*treatment at MANOVA